Fujifilm to make AAVs for Regenxbio gene therapies

By Staff Reporter

- Last updated on GMT

GettyImages/kirstypargeter
GettyImages/kirstypargeter
Regenxbio says a manufacturing contract with Fujifilm Diosynth Biotechnologies will support its gene therapy candidates.

Under terms of the deal, contract development and manufacturing organisation (CDMO) Fujifilm Diosynth Biotechnologies will manufacture Regenxbio’s lead candidates – including RGX-314 and RGX-501 – as it looks to take them through late-stage clinical trials and into commercialisation.

Speaking this week on a financial call, CEO Ken Mills said the deal with Fujifilm “expanded the breadth and depth capabilities in development”​ and secured “access to long term dedicated cGMP suite capacity”​ at up to a 2,000L scale.

“This partnership enhances our existing internal capabilities through which we were able to produce NAV [adeno-associated virus] AAV at up to 200 liter scale and it fortifies our position of leadership in AAV manufacturing.”

All is Regenxbio’s candidates use viral vectors from its proprietary gene delivery platform, called the NAV Technology Platform. The technology uses NAV AAVs as a delivery vehicle by inserting a healthy gene inside the NAV’s shell, before administering the vector into the patient. Once inside the body the healthy gene payload is delivered to an affected cell’s nucleus where it transcribes its DNA into RNA. This in turn encodes a specific protein that the body was missing and, when the body replicates the cell, it has the potential to correct the disease.

Regenxbio has its own facility in Rockville, Maryland and the deal does not restrict the firm from investing in its own cGMP manufacturing capabilities.

Fujifilm has invested in commercial gene therapy capabilities on the back of increased demand from biopharma​.

Earlier this year, the CDMO opened an 80,000 square-foot plant at its site in Texas, acquired from Kalon Therapeutics in 2014​​.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars